Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TERT | O14746 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18387404 | 0.98 | ALDH1A1 (0.34) | ALDH1A1MAPTLMNAHPGDKDM4E | |
| SCHEMBL17033341 | 0.87 | AHR (0.39) | ALDH1A1MAPTLMNAHPGDKDM4E | |
| SCHEMBL17033180 | 0.86 | ALDH1A1 (0.36) | ALDH1A1MAPTLMNAHPGDKDM4E | |
| SCHEMBL17028346 | 0.86 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAHPGDKDM4E | |
| SCHEMBL18387336 | 0.81 | TERT (0.33) | ALDH1A1MAPTHPGDKDM4EHTT | |
| SCHEMBL18387405 | 0.79 | ALDH1A1 (0.33) | ALDH1A1MAPTLMNAHPGDKDM4E | |
| SCHEMBL18387409 | 0.79 | ADCY1 (0.33) | ALDH1A1LMNAHPGDKDM4ETSHR | |
| SCHEMBL17033242 | 0.78 | ALDH1A1 (0.36) | ALDH1A1MAPTLMNAHPGDKDM4E | |
| SCHEMBL18387341 | 0.78 | TERT (0.33) | POLBTERT | |
| SCHEMBL18387337 | 0.78 | TYR (0.31) | ALDH1A1MAPTHPGDKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170018717-A1 | NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-01-19 | — | — | US | disclosed |
| US-20170018717-A1 | NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-01-19 | — | — | US | disclosed |
| WO-2015125125-A1 | NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS | BASF SE (DE) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170018717-A1 | NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS | CHRM2, RPS4Y1, CHRM4 | ALDH1A1 3820/4885MAPT 4448/4885LMNA 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.